The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
BioRestorative Therapies Pretax Margin % Related Terms
BioRestorative Therapies Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:9OF vs CVKD, JSPR, APRE: Pretax Margin % Comparison
For the Biotechnology subindustry, BioRestorative Therapies's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioRestorative Therapies Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioRestorative Therapies's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where BioRestorative Therapies's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioRestorative Therapies (STU:9OF) has a Pretax Margin % of -9,315.00% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on BioRestorative Therapies and its competitors. According to the industry distribution chart, BioRestorative Therapies ranks #818 out of 943 companies in the Biotechnology industry, placing it in the top 86.7%.
Is BioRestorative Therapies' Pretax Margin % too high?
BioRestorative Therapies' current Pretax Margin % is -9,315.00%. Based on the distribution chart, BioRestorative Therapies ranks #818 out of 943 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BioRestorative Therapies has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioRestorative Therapies' Pretax Margin % compare to CVKD and JSPR?
According to the Biotechnology industry distribution chart, BioRestorative Therapies ranks #818 out of 943 companies for Pretax Margin %. This places BioRestorative Therapies in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on BioRestorative Therapies and its competitors. BioRestorative Therapies's current Pretax Margin % is -9,315.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioRestorative Therapies stock overvalued right now?
Based on GuruFocus' analysis, BioRestorative Therapies (STU:9OF) is currently considered Possible Value Trap. The stock's GF Value™ is €1.27, compared to a current price of €0.32 — trading 75.1% below its estimated fair value. The current Pretax Margin % is -9,315.00%. BioRestorative Therapies' overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For BioRestorative Therapies (STU:9OF), the current Pretax Margin % is -9,315.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioRestorative Therapies (STU:9OF) Overvalued in 2026?
Based on GuruFocus' analysis, BioRestorative Therapies stock appears to be undervalued.
The current stock price of €0.32 is trading 75.1% below its estimated GF Value™ of €1.27.
GuruFocus considers BioRestorative Therapies to be Possible Value Trap.
Key valuation signals for STU:9OF:
Pretax Margin %: -9,315.00%
GF Value™: €1.27 vs. price of €0.32 (75.1% below fair value)
No single metric tells the full story. See the STU:9OF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
60GF Score
Get the complete analysis for STU:9OF
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:9OF has been successfully added to your 
